Global Hemp Group (GBHPF) Fair Value & Analysis
Healthcare · US · Market cap $2.4K
Global Hemp Group
GBHPF · US
Fair value as of: Aug 18, 2026
From 2 valuation models · updated today
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range $0.0001 – $1.54 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
Global Hemp Group (GBHPF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $1. Fundamentals as of Aug 18, 2026
For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 0%, GBHPF screens cheaper than that median.
Notify me when GBHPF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 8
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Global Hemp Group Inc. engages in health and wellness, and industrial hemp businesses. The Industrial Hemp division primarily focuses on the environmental uses of hemp for construction and bio-energy sources for carbon-negative footprint.
Full company description
Global Hemp Group Inc. engages in health and wellness, and industrial hemp businesses. The Industrial Hemp division primarily focuses on the environmental uses of hemp for construction and bio-energy sources for carbon-negative footprint. The Health and Wellness Division focuses on the acquisition of exclusive licensing of patents and IP for the commercialization of hemp formulations that have been independently pre-clinically tested. The company was formerly known as Arris Holdings Inc. and changed its name to Global Hemp Group Inc. in March 2014. Global Hemp Group Inc. was incorporated in 2009 and is headquartered in North Vancouver, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Global Hemp Group reported revenue of $0 in FY2023 versus $2.6K in FY2019. Reported net income was −$2.6M in FY2023.
Watch GBHPF: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 625 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Global Hemp Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Global Hemp Group (GBHPF) overvalued or undervalued?
What is the fair value of GBHPF?
What is the quality score of GBHPF?
What is the revenue of Global Hemp Group (GBHPF)?
What is the net profit margin of GBHPF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Global Hemp Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.